source
- Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to VertexSionna Therapeutics said its lead cystic fibrosis drug did not meet primary endpoints in an early-stage study, marking a setback for the company. The result reduces expectations that Sionna could…
- Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 successSilence Therapeutics announced that its siRNA candidate divesiran achieved its primary endpoint in a Phase 2 study in patients with polycythemia vera, a rare blood cancer. The trial results showed…